News

Crocs' Impressive Holiday Performance Boosts Investor Confidence

Crocs' Impressive Holiday Performance Boosts Investor Confidence

Crocs Reports Strong Holiday Quarter Performance

The footwear maker announced impressive adjusted earnings per share of $2.29, surpassing the anticipated $1.90 consensus. Revenue reached $957.64 million, comfortably exceeding the expected $922.33 million.

Performance Insights and Margins

Despite the positive earnings, the company experienced a decline in its fourth-quarter adjusted gross margin, falling to 54.7% from the 57.9% recorded the previous year. Operating income saw a significant drop of 26.8% to $146 million, resulting in a narrowed operating margin of 15.3% compared to the 20.2% observed previously. Adjusted operating income also fell by nearly 19.7%, down to $161 million with a corresponding 16.8% margin.

Andrew Rees, the CEO, expressed satisfaction with the quarter's performance, emphasizing, "We ended the year on an optimistic note with a better-than-expected holiday quarter."

Brand Analysis

The Crocs brand generated $768 million in revenue, reflecting a 0.8% growth. In contrast, HEYDUDE reported a decline of 16.9% with $189 million. International sales for Crocs surged by 14.1% to $332 million, helping to offset a 7.4% decrease in North American sales.

Company Financial Health

In terms of share performance, the company repurchased 6.5 million shares for $577 million during the last year. Ending the year with cash reserves of $130 million, total borrowings reduced to $1.23 billion, while inventories increased to $369 million. Capital expenditures amounted to $51 million.

Outlook for Q1 and FY26

Looking ahead, Crocs provided an optimistic guidance for the first quarter of 2026, forecasting adjusted EPS between $2.67 and $2.77—well above the $2.52 consensus estimate. However, the company also anticipates a revenue decline ranging from 3.5% to 5.5% year over year. Crocs predicts that sales from its core brand will fall slightly, while HEYDUDE revenue is projected to drop between 15% and 18%. For fiscal 2026, the revenue outlook suggests a minor decrease of around 1% to a slight increase year over year, with Crocs brand sales expected to grow up to 2%.

Additionally, Crocs aims to achieve adjusted EPS between $12.88 and $13.35, exceeding the $12.10 consensus estimate. The planned capital expenditure ranges between $70 million and $80 million, with an expected adjusted tax rate of 18%.

CEO Rees remarked, "As we enter 2026, we have renewed confidence in our growth strategy, strengthened across various channels and geographies. We've successfully identified $100 million in cost savings for 2026 to drive enhanced efficiency and ensure continued investments in our brands while fostering consumer relationships."

Elevated Short Interest Levels

Currently, Crocs has a short float of 6.058 million shares, which equates to 13.72% of its publicly traded float, indicating a heightened level of short interest among investors betting against the stock.

CROX Price Movement: Crocs shares saw a robust increase of 14.23% reaching $94.50 during premarket trading.

Frequently Asked Questions

What were Crocs' latest earnings per share?

Crocs reported adjusted earnings per share of $2.29 for the latest quarter.

How did Crocs' revenue perform compared to expectations?

Revenue reached $957.64 million, exceeding the anticipated $922.33 million.

What is the outlook for Crocs in the first quarter of 2026?

Crocs expects adjusted EPS in the range of $2.67 to $2.77, while revenue may decline by 3.5% to 5.5% year over year.

What are the projections for Crocs' revenue in FY26?

The company anticipates revenue to be down about 1% to possibly slightly positive by year-end.

What does the elevated short float indicate about Crocs?

The short float of 13.72% reflects a significant bearish sentiment among investors toward the stock.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 45

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Cirba Solutions Welcomes Angie Stoskopf as VP of HR

Updated Category News Views 124

Cirba Solutions Welcomes New Executive Leadership Cirba Solutions, the leading battery recycling materials and management company, has announced the recent appointment of Angie Stoskopf as Vice President of People & Talent. This strategic decision underscores the company's commitment to enhancing its human resources capabilities, enabling them to support continued growth...

Continue Reading
Stay Warm This Winter With Mini-Split Heating Solutions

Updated Category News Views 65

Discover Efficient Heating with Mini-Split Systems As winter approaches and temperatures begin to drop, many homeowners are searching for effective and energy-efficient heating solutions. Mr. Mini Split is a leading provider in offering innovative mini-split heating and cooling systems that enhance comfort while maintaining energy efficiency. Why Choose Mini-Split...

Continue Reading
Leadership Changes at TowerCom Following Chris Colton's Passing

Updated Category News Views 1029

TowerCom Announces Significant Leadership Changes TowerCom, a seasoned developer of cell towers for over three decades, is thrilled to unveil pivotal leadership appointments aimed at furthering its growth and operational success. The company has elevated George Davis to the position of Chief Executive Officer, Matt Richard has been promoted to Chief Financial Officer,...

Continue Reading
Tencent Music's Strategic Growth Amidst Listener Decline

Updated Category News Views 201

Tencent Music's Robust performance amidst challenges Tencent Music Entertainment (NYSE: TME) recently showcased its impressive quarterly growth, gaining attention in the market as its shares surged. The latest financial results highlighted a revenue of $1.19 billion, reflecting a remarkable 20.6% increase year-over-year (Y/Y), a sign of strong demand and resilience in the...

Continue Reading
Bowen Acquisition Corp. Stock Hits Notable Low Amid Market Struggles

Updated Category News Views 192

Bowen Acquisition Corp. Experiences Significant Stock Movement In a financial landscape characterized by considerable fluctuations, Bowen Acquisition Corp. (BOWN) has seen its stock drop to a new 52-week low, hitting $10.08. This dip is noteworthy for a company with a market capitalization of around $100 million, particularly since BOWN is often recognized for its...

Continue Reading